Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice
Controlled trialOther animals
- Design
- Controlled trial
- Subjects
- not stated in abstract (db/db diabetic mice and controls)
- Dose used in the study
- not stated in abstract
- Duration
- 4 weeks of carnosine treatment
- What was measured
- Kidney carnosinase (CN1) activity, renal carnosine, anserine and homocarnosine, proteinuria and vascular permeability in db/db mice and controls.
What the authors reported
Kidney CN1 activity increased with age and was significantly higher in diabetic mice than controls. Renal carnosine was unaffected, but anserine was tenfold lower in db/db mice (0.24 +/- 0.2 vs 2.28 +/- 0.3 nmol/mg protein, p < 0.001); homocarnosine was low in both groups. Four weeks of carnosine decreased CN1 activity in diabetic mice (0.32 to 0.05, p < 0.01) to close to normal, raised renal anserine (0.24 to 5.7, p < 0.01) and left carnosine unchanged (53 vs 61 nmol/mg protein, not significant). It also halved proteinuria and reduced vascular permeability to one-fifth. The authors conclude carnosine largely prevents the alterations of renal carnosine metabolism.
Limits of this study
Mouse model; dose, route and group sizes not given in the abstract; units reported in the abstract are inconsistent between measures. Full text not read. Route of carnosine not stated in abstract; rodents lack serum carnosinase, so oral results do not carry over to people.
Source
PubMed 21833769 · doi:10.1007/s00726-011-1046-4
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.